SEARCH RESULTS FOR:

United States
Pharma & Life Sciences

Pooling Its Force: U.S. Biopharmaceutical Industry Channels R&D Focus Amid Changing Tides

United States Biopharmaceuticals 2017
In a time of uncertainty across the board, the United States is still "going boldly” ahead, bringing us innovation and constantly adapting its business model.
Mining
Australia

Peter Jacobs

SENIOR VICE PRESIDENT – ASIA PACIFIC, FORACO
Western Australia Mining 2017 Pre-Release
Mining
Canada

Robin Longe

PARTNER, NORTON ROSE FULBRIGHT FEBRUARY 28, 2017
British Columbia, Yukon and Vancouver Mining 2017
Norton Rose Fulbright speaks to GBR about its recent merger with Bull Housser and regulations effecting mining in British Colombia.
Mining
Argentina

Andrea Polizzotto

DIRECTOR OF RADIO ESTACION MINERA & JUDICIAL AND COMMUNITY MEDIATOR LAWYER, SAN JUAN
Argentina Mining 2017 E&MJ Release
Singapore
Aerospace

Singapore Aerospace 2017

Aerospace
Canada

Ontario Aerospace 2017

Mining
Australia

Peter Hall

CHIEF EXECUTIVE OFFICER, AUSTRALIAN DRILLING INDUSTRY ASSOCIATION
Western Australia Mining 2017 Pre-Release
Western Australia drilling companies innovate technologies to increase productivity in a stretching sector.
Aerospace
Canada

Ontario’s Aerospace R&D Ecosystem

Ontario Aerospace 2017
Ontario must upgrade its established advanced manufacturing industry, embrace disruptive technologies and promote innovation.
Aerospace
Italy

Internationalisation: The Road to Success for Italy’s SMEs

Italy Aerospace 2016
Italian aerospace companies are generally small and must banned together if they are to be considered for large scale contracts.
Aerospace
Canada

Quebéc Aerospace: Education

Québec Aerospace 2017
Québec owes a great part of its success in the aerospace industry to the quality of education and training that the province can offer.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL